ERBB2 and gastric cancer: Major problems in the evaluation of HER2 positivity outside of breast and gastric cancer are (1) the lack of standardized and site-specific scoring systems and (2) HER2 amplification is often assessed using different methods that are neither standardized nor comparable across different laboratories/trials.